Patents by Inventor Wendy Ann Dulin

Wendy Ann Dulin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230061743
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Application
    Filed: May 27, 2022
    Publication date: March 2, 2023
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • Sustained release pharmaceutical compositions
    Patent number: 11179369
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: November 23, 2021
    Assignee: Wyeth LLC
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20200138781
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Application
    Filed: November 1, 2019
    Publication date: May 7, 2020
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • Sustained release pharmaceutical compositions
    Patent number: 10463648
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 5, 2019
    Assignee: Wyeth, LLC
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180344695
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • Pharmaceutical compositions of estrogenic agents
    Patent number: 7759386
    Abstract: This invention relates to novel pharmaceutical carrier or excipient systems and oral pharmaceutical compositions comprising 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: July 20, 2010
    Assignee: Wyeth LLC
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Jiwaji Gulabrao Suryawanshi
  • PHARMACEUTICAL COMPOSITIONS OF ESTROGENIC AGENTS
    Publication number: 20080269198
    Abstract: This invention relates to novel pharmaceutical carrier or excipient systems and oral pharmaceutical compositions comprising 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 20, 2007
    Publication date: October 30, 2008
    Applicant: WYETH
    Inventors: Eric Joel BENJAMIN, Wendy Ann DULIN, Jiwaji Gulabrao SURYAWANSHI
  • Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
    Publication number: 20080199518
    Abstract: The present invention relates to controlled-release beads comprising diquinoline-substituted piperazine-piperidine compounds, such as 5-fluoro-8-{4-[4-[(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, or pharmaceutically acceptable salts thereof; to multiple particulate formulations comprising such beads; to methods of preparing such beads; and to methods of treating 5-HT1A-related disorders using such beads and/or multiple particulate formulations.
    Type: Application
    Filed: November 27, 2007
    Publication date: August 21, 2008
    Applicant: Wyeth
    Inventors: Mannching Sherry Ku, Wendy Ann Dulin, Yanning Lin
  • Bazedoxifene treatment regimens
    Publication number: 20040063692
    Abstract: This invention relates to extended dosing regimens for the selective estrogen receptor modulator bazedoxefine (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1 H-indol-5-ol).
    Type: Application
    Filed: June 13, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Barry Samuel Komm, Simon Nicholas Jenkins, James Charles Ermer, Mark Andrew Collins, Geraldine Marie Ferron, Pol Boudes, Wendy Ann Dulin